Atlas Venture Life Science Advisors, LLC Akero Therapeutics, Inc. Transaction History

Atlas Venture Life Science Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$41.19 - $52.25 $9.68 Million - $12.3 Million	-235,000 Reduced 39.55%	359,251 $18.2 Million
Q4 2022 Feb 14, 2023	SELL	$33.44 - $54.8 $13.4 Million - $21.9 Million	-400,000 Reduced 40.23%	594,251 $32.6 Million
Q3 2022 Nov 09, 2022	SELL	$10.15 - $34.05 $12.6 Million - $42.2 Million	-1,238,000 Reduced 55.46%	994,251 $33.9 Million
Q4 2021 May 16, 2022	BUY	$19.87 - $26.24 $44.4 Million - $58.6 Million	2,232,251 New	2,232,251 $47.2 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.52B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Atlas Venture Life Science Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Atlas Venture Life Science Advisors, LLC with notifications on news.